News
Artificial Intelligence and Deep Learning as the Future of Glaucoma Diagnosis
Glaucoma represents a group of eye diseases characterized by changes to the optic nerve. It is the second most common cause of blindness, currently affecting more than 90 million people worldwide. It is projected that by 2040, the number of people diagnosed with glaucoma will nearly double. According to a study published in the journal Biomedical Engineering Online in December 2023, effective screening examinations utilizing the diagnostic skills of artificial intelligence will become increasingly important in ophthalmology.
MUDr. Jana Zárubová: Experiences with buccal midazolam in real practice are positive and we can significantly improve patients' quality of life
Recently, it has emerged as an alternative to traditionally rectally administered diazepam for…
IEC 2023: Key Challenges for Epilepsy Patients Include Status Epilepticus and Anxiety Management
Why is anxiety a significant issue for epilepsy patients? What do current insights say about the…
Ocrelizumab in the Treatment of Multiple Sclerosis – 10-Year Data
Multiple sclerosis (MS) is a lifelong disease with a high risk of permanent disability. Current…
Long-term Efficacy and Safety of Mavacamten in the Treatment of Obstructive HCM
Interim results of the MAVA-LTE study provide the latest data on the long-term safety and efficacy…
Mavacamten in the Treatment of HCM in Patients Referred for Septal Reduction
Extended 56-week follow-up of patients with hypertrophic cardiomyopathy (HCM) resistant to current…
How Does Myelodysplastic Syndrome Affect Patients' Quality of Life?
Myelodysplastic syndrome (MDS) is a heterogeneous group of disorders of hematopoietic stem cells…
Planning Surgery Using 3D Printing in Practice – Case Study
In October 2023, an article by neurosurgeons from Leipzig University was published in the journal …
Immunomodulation and Romiplostim − What Does the Recently Published iROM Study Say?
Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the…
ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia
The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in…